Nuclear factor-Y binding to the topoisomerase IIα promoter is inhibited by both the p53 tumor suppressor and anticancer drugs

Molecular Pharmacology

Volumn 63, Issue 2, 2003, Pages 359-367

  Joshi, Ashish A ^a,c   Wu, Zhong ^a,d   Reed, Robin F ^a   Suttle, D Parker ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Roquette America   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; AMSACRINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CCAAT BINDING FACTOR; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ELLIPTICINE; ETOPOSIDE; MITOXANTRONE; MUTANT PROTEIN; NUCLEAR FACTOR; NUCLEAR FACTOR Y; PROTEIN P53; TENIPOSIDE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG BINDING SITE; DRUG INHIBITION; DRUG TARGETING; ENZYME MECHANISM; GENE EXPRESSION REGULATION; GENE LOCATION; MITOSIS RATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING;

3T3 CELLS; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BINDING SITES; CCAAT-BINDING FACTOR; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037311674     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.2.359     Document Type: Article

References (46)

1. Agoff SN, Hou J, Linzer DIH, and Wu B (1993) Regulation of the human hsp70 promoter by p53. Science (Wash DC) 259:84-87.
2. Bolognese F, Wasner M, Dohna CL, Gurtner A, Ronchi A, Muller H, Manni I, Mossner J, Piaggio G, Mantovani R, et al. (1999) The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene 18:1845-1853.
3. Borellini F and Glazer RI (1993) Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J Biol Chem 268:7923-7928.
4. Chen G, Templeton D, Suttle DP, and Stacey DW (1999) Ras stimulates DNA topoisomerase IIα through MEK: a link between oncogenic signaling and a therapeutic target. Oncogene 18:7149-7160.
5. Chin K-V, Ueda K, Pastan I, and Gottesman MM (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (Wash DC) 255:459-462.
6. Cho Y, Gorina S, Jeffrey PD, and Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Wash DC) 265:346-355.
7. Corbett AH and Osheroff N (1993) When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 6:585-597.
8. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, and Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27:8861-8869.
9. Drake FH, Hofmann GA, Mong S-M, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, and Mirabelli CK (1989) In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49:2578-2583.
10. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
11. Falck J, Jensen PB, and Sehested M (1999) Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase IIα gene. J Biol Chem 274:18753-18758.
12. Furukawa M, Uchiumi T, Nomoto M, Takano H, Morimoto RI, Naito S, Kuwano M, and Kohno K (1998) The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase IIα gene by heat shock. J Biol Chem 273:10550-105555.
13. Goldwasser F, Bae I, Pommier Y, and Fornace AJ Jr (1999) Evidence of a reduced DNA topoisomerase II mRNA expression after ionizing radiation. Anticancer Res 19:3167-3171.
14. 6-methylguanine-DNA methyltransferase gene. Cancer Res 56:2029-2032.
15. Herzog CE and Zwelling LA (1997) Evaluation of a potential regulatory role for inverted CCAAT boxes in the human topoisomerase IIα promoter. Biochem Biophys Res Commun 232:608-612.
16. Hochhauser D, Stanway CA, Harris AL, and Hickson ID (1992) Cloning and characterization of the 5′-flanking region of the human topoisomerase IIα gene. J Biol Chem 267:18961-18965.
17. Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, Marin C, Bellocq JP, Oudet P, and Bronner C (2000) ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIα expression. Cancer Res 60:121-128.
18. Hu Z, Jin S, and Scotto KW (2000) Transcriptional activation of MDR1 gene by UV irradiation. Role of NF-Y and Spl. J Biol Chem 275:2979-2985.
19. Isaacs RJ, Harris AL, and Hickson ID (1996) Regulation of the human topoisomerase IIα gene promoter in confluence-arrested cells. J Biol Chem 271:16741-16747.
20. Jung MS, Yun J, Chae HD, Kim JM, Kim SC, Choi TS, and Shin DY (2001) p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor. Oncogene 20:5818-5825.
21. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311.
22. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, and Fornace AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597.
23. Kley N, Chung RY, Fay S, Loeffler JP, and Seizinger BR (1992) Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res 20:4083-4087.
24. Liu X, Miller CW, Koeffler PH, and Berk AJ (1993) The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID and a neighboring p53 domain inhibits transcription. Mol Cell Biol 13:3291-3300.
25. Lum LS, Sultzman LA, Kaufman RJ, Linzer DI, and Wu BJ (1990) A cloned human CCAAT-box-binding factor stimulates transcription from the human hsp70 promoter. Mol Cell Biol 10:6709-6717.
26. Maity SN and de Crombrugghe B (1998) Role of the CCAAT-binding protein CBF/NF-Y in transcription. Trends Biochem Sci 23:174-178.
27. Maity SN, Sinha S, Ruteshouser EC, and De Crombrugghe B (1992) Three different polypeptides are necessary for DNA binding of the mammalian heteromeric CCAAT binding factor. J Biol Chem 267:16574-16580.
28. Mantovani R (1998) A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res 26:1135-1143.
29. Mantovani R, Li XY, Pessara U, Hooft van Huisjduijnen R, Benoist C, and Mathis D (1994) Dominant negative analogs of NF-YA. J Biol Chem 269:20340-20346.
30. Matsuo K-I, Kohno K, Sato S, Uchiumi T, Tanimura H, Yamada Y and Kuwano M (1993) Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer cells. Cancer Res 53:1085-1090.
31. Momand J, Zambetti GP, Olson DC, George D, and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
32. Morgan SE and Beck WT (2001) Role of an inverted CCAAT element in human topoisomerase IIα gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells. Mol Pharmacol 59:203-211.
33. Nitiss JL, Pourquier P, and Pommier Y (1997) Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res 57:4564-4569.
34. Ng S-W, Eder JP, Schnipper LE, and Chan VTW (1995) Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase IIα gene. J Biol Chem 270:25850-25858.
35. Okamoto K and Beach D (1994) Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO (Eur Mol Biol Organ) J 13:4816-4822.
36. Park SH, Yoon JH, Cho HA, Do Kwon Y, Seong RH, Hong SH, and Park SD (1995) Isolation and characterization of the promoter region of the rat DNA topoisomerase IIα gene. J Biochem (Tokyo) 118:725-733.
37. Ravi R, Mookerjee B, van Hensbergen Y, Bedi GC, Giordano A, El-Deiry WS, Fuchs EJ, and Bedi A (1998) p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res 58:4531-4536.
38. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, and Vikhanskaya F (1996) p53 regulates the minimal promoter of the human topoisomerase IIα gene. Nucleic Acids Res 24:4464-4470.
39. Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran E, Berger SL, and Halazonetis TD (1997) CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res 57:3693-3696.
40. Sinha S, Kim IS, Sohn KY, De Crombrugghe B, and Maity SN (1996) Three classe of mutations in the A subunit of the CCAAT-binding factor. Mol Cell Biol 16:328-337.
41. Takano H, Ise T, Nomoto M, Kato K, Murakami T, Ohmori H, Imamura T, Nagatani G, Okamoto T, Ohta R, et al. (1999) Structural and functional analysis of the control region of the human DNA topoisomerase IIα gene in drug-resistant cells. Anticancer Drug Des 14:87-92.
42. Vayssade M, Faridoni-Laurens L, Benard J, and Ahomadegbe JC (2002) Expression of p53-family members and associated target molecules in breast cancer cell lines in response to vincristine treatment. Biochem Pharmacol 63:1609-1617.
43. Wang Q, Zambetti GP, and Suttle DP (1997) Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol Cell Biol 17:389-397.
44. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, and Drake FH (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2:209-214.
45. Yun J, Chae H-D, Choy HE, Chung J, Yoo H-S, Han M-H, and Shin DY (1999) p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 274:29677-29682.
46. Zambetti GP and Levine AJ (1993) A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855-865.